Investor Relations Captor Therapeutics ®
Presentations & Posters
-
-
Captor Corporate Presentation 2024
-
Pioneering Targeted Protein Degraders For Human Health (Trigon Oct2024)
-
A New Modality for the Management of Inflammation: NEK7 Degradation
-
Captor H1 2024 Results
-
Captor Q1 2024
-
MCL-1: A Target with Immense Potential in Oncology
-
Captor Annual Report (April 2024)
-
Targeted Protein Degradation Q1 2024 Update
-
-
-
Investor FactSheet Q3 2022
-
ESMO Asia Congress, Singapore -poster
-
ENA 2022, Barcelona - poster
-
5th Annual Targeted Protein Degradation Summit, Boston - poster
-
Corporate Presentation H1/2022
-
R&D Day
-
Investor Factsheet Q1 2022
-
Investor Day Presentation
-
CT-01 molecular target disclosure – what does this mean for project development?
-
2nd Annual Targeted Protein Degradation Europe Summit
-
Promising research results in two flagship projects
-